Drug Information
| Drug General Information | |||||
|---|---|---|---|---|---|
| Drug ID |
D0X8QP
|
||||
| Former ID |
DIB001247
|
||||
| Drug Name |
FOSOPAMINE
|
||||
| Synonyms |
S-2055; SIM-2055; Fosopamine < Rec INN >; N-Methyldopamine 4-O-phosphate; 4-[2-(Methylamino)ethyl]-1,2-benzenediol 1-(dihydrogen phosphate)
|
||||
| Drug Type |
Small molecular drug
|
||||
| Indication | Hypertension [ICD9: 401; ICD10:I10-I16] | Discontinued in Phase 2 | [1] | ||
| Structure |
|
Download2D MOL |
|||
| Formula |
C9H14NO5P
|
||||
| Canonical SMILES |
CNCCc1ccc(OP(=O)(O)O)c(O)c1
|
||||
| InChI |
1S/C9H14NO5P/c1-10-5-4-7-2-3-9(8(11)6-7)15-16(12,13)14/h2-3,6,10-11H,4-5H2,1H3,(H2,12,13,14)
|
||||
| InChIKey |
WHEGQKBWPSOMHG-UHFFFAOYSA-N
|
||||
| CAS Number |
CAS 103878-96-2
|
||||
| PubChem Compound ID | |||||
| Target and Pathway | |||||
| Target(s) | D(2) dopamine receptor | Target Info | Modulator | [2], [3] | |
| KEGG Pathway | Rap1 signaling pathway | ||||
| cAMP signaling pathway | |||||
| Neuroactive ligand-receptor interaction | |||||
| Gap junction | |||||
| Dopaminergic synapse | |||||
| Parkinson's disease | |||||
| Cocaine addiction | |||||
| Alcoholism | |||||
| PANTHER Pathway | Heterotrimeric G-protein signaling pathway-Gi alpha and Gs alpha mediated pathway | ||||
| Heterotrimeric G-protein signaling pathway-Gq alpha and Go alpha mediated pathway | |||||
| Dopamine receptor mediated signaling pathway | |||||
| Nicotine pharmacodynamics pathway | |||||
| Reactome | Dopamine receptors | ||||
| G alpha (i) signalling events | |||||
| WikiPathways | Hypothetical Network for Drug Addiction | ||||
| Monoamine GPCRs | |||||
| GPCRs, Class A Rhodopsin-like | |||||
| Genes and (Common) Pathways Underlying Drug Addiction | |||||
| GPCR ligand binding | |||||
| GPCR downstream signaling | |||||
| Nicotine Activity on Dopaminergic Neurons | |||||
| References | |||||
| REF 1 | Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800002585) | ||||
| REF 2 | Development of dopaminergic drugs for the chronic treatment of congestive heart failure. J Auton Pharmacol. 1990;10 Suppl 1:s85-93. | ||||
| REF 3 | Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. 2015 | ||||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.